Advertisements

Мотинорм

Quick links to important sections

Мотинорм

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Мотинорм

Property Description
Active Ingredient Domperidone
Form Oral Tablet, Oral Suspension, Oral Drops, Suppository
Pharmacological Class Antiemetic and Prokinetic Agent
General Purpose Managing nausea, vomiting, and impaired gastrointestinal motility
Origin Synthetic Benzimidazole Derivative

What is Мотинорм and its Core Active Ingredient?

Мотинорм is a trade-name pharmaceutical product containing the single active ingredient, Domperidone. This compound is a synthetic chemical derivative (benzimidazole) and is the foundation for several pharmaceutical preparations for oral and rectal route of administration, including the common oral tablet, oral suspension, oral drops, and suppository forms.

As a single-ingredient medicine, Мотинорм focuses entirely on the effects of Domperidone, which are related to regulating the gastrointestinal system. Domperidone's pharmacological profile is defined by its antiemetic and prokinetic actions. As such, the medicine is clinically recognized for addressing two distinct functional issues: sickness and poor digestive movement.


Pharmacological Class: Antiemetic and Prokinetic Agent

Мотинорм belongs to two simultaneous pharmacological classes: it is an antiemetic agent and a prokinetic agent. This dual classification defines its therapeutic purpose as controlling the sensation of sickness while stimulating the physical movement of the stomach and intestines. Domperidone acts as a peripheral dopamine D2-D3 receptor antagonist. This explains its typical use in scenarios such as relieving the discomfort associated with delayed gastric emptying.

The term antiemetic denotes its function in preventing or relieving nausea and vomiting, while prokinetic refers to its ability to enhance the tone and coordinated movement of the digestive tract. The medicine's peripheral-selective mechanism ensures that its primary actions are focused on the gut and the chemoreceptor trigger zone (CTZ), minimizing influence on the central nervous system.

Regulatory References

  1. European Medicines Agency
Advertisements

What side effects are possible with Мотинорм?

Possible Side Effects and Safety Information for Мотинорм (Domperidone)

Adverse Reaction Profile

Мотинорм is associated with a small, increased risk of serious cardiovascular events, including QT interval prolongation, ventricular arrhythmia, and sudden cardiac death. Regulatory bodies have observed that this risk is higher in patients over 60 years of age and when the total daily oral dose exceeds 30 mg. Cardiac arrest has been reported.

Non-cardiac adverse reactions are categorized by frequency:

Frequency System-Organ Class Key Adverse Reactions
Common General Dry mouth.
Uncommon Endocrine/Reproductive Galactorrhea, breast enlargement/gynaecomastia, amenorrhea, decreased libido.
Uncommon General/Skin Asthenia (weakness), pruritus, rash, hypersensitivity.
Frequency Unknown Nervous System Extrapyramidal symptoms (uncontrolled movements), somnolence, headache, seizures.
Frequency Unknown Cardiovascular Torsade de pointes, sudden cardiac death.

Safety Restrictions and Contraindications

To mitigate cardiac risk, Мотинорм is subject to strict limitations. It is contraindicated in individuals with moderate or severe hepatic (liver) impairment, pre-existing cardiac conduction disorders (such as prolonged QTc interval), or underlying cardiac conditions like congestive heart failure. It must also not be used concurrently with other medicines known to prolong the QT interval or with potent CYP3A4 inhibitors, which can increase domperidone concentration in the blood.

Safety monitoring notes emphasize the importance of using the lowest effective dose for the shortest possible duration, which should generally not exceed one week for acute treatment. Individuals with electrolyte imbalances (hypokalaemia or hypomagnesaemia) are also considered at a higher proarrhythmic risk, requiring caution and monitoring.

Advertisements

Overdose and Emergency Response

Overdose of Domperidone (Мотинорм) is documented in regulatory sources and may affect both the Central Nervous and Cardiovascular systems. Documented central nervous system manifestations include agitation, somnolence (drowsiness), disorientation, impaired consciousness, and convulsions. Patients may also exhibit movement disorders classified as extrapyramidal reactions, such as dystonia and oculogyric crises.

The most severe documented concern is the risk to the cardiovascular system, which involves QT interval prolongation on the electrocardiogram. This can escalate to life-threatening ventricular arrhythmias like Torsade de Pointes and potentially result in cardiac arrest or death.

Due to these severe risks, government regulatory bodies mandate that any suspected overdose requires immediately seeking urgent medical attention or contacting emergency services. Management must include close clinical observation and continuous ECG monitoring until the patient is stable.

There is no specific antidote known for Domperidone overexposure. Management is therefore strictly symptomatic and supportive. Supportive procedural steps may involve the administration of activated charcoal and, if appropriate, gastric lavage. Regulatory documents note that infants and children and patients with impaired renal function may be more susceptible to severe overdose effects.

Advertisements

Therapeutic Uses of Мотинорм

Quick Facts: Мотинорм

  • Manages feelings of nausea.
  • Helps control vomiting episodes.
  • Assists in reducing symptoms of indigestion (dyspepsia).
  • Supports the management of delayed stomach emptying (gastroparesis).

Мотинорм is an authorized medication indicated for the symptomatic management of specific gastrointestinal discomforts. Its primary role is to provide relief from feelings of nausea and to help control vomiting episodes in adults and adolescents when prescribed by a healthcare provider.

This medication is utilized to address symptoms associated with functional dyspepsia, a common condition that may include upper abdominal fullness, bloating, and discomfort that arises shortly after beginning or completing a meal.

Furthermore, Мотинорм may be a component in the established treatment plan for gastroparesis, a condition characterized by delayed stomach emptying that leads to similar gastrointestinal symptoms. The therapeutic approach seeks to support and modulate digestive motility, which may help improve overall patient comfort and symptom resolution.

Advertisements

Eligibility and Restrictions for Use

Eligibility for Мотинорм (Domperidone)

Official regulatory information defines strict parameters for who can and cannot use Мотинорм. The medicine is authorized only for adults and adolescents aged 12 years and older and weighing 35 kg or more.

Use is not recommended for children under 12 years of age or adolescents under 35 kg due to lack of established efficacy and cardiac safety considerations.

Contraindications (Must NOT Use)

The most severe restriction applies to patients with:

  • Cardiac Risks: Existing prolongation of the QTc interval, significant electrolyte disturbances (like hypokalemia), bradycardia, or underlying cardiac diseases such as congestive heart failure.
  • Hepatic Impairment: Patients with moderate or severe liver impairment.
  • Gastrointestinal Conditions: Cases where stimulating gastric motility could be harmful, such as in the presence of gastrointestinal haemorrhage, mechanical obstruction, or perforation.
  • Endocrine Conditions: A prolactin-releasing pituitary tumour (prolactinoma).
  • Drug Interactions: Co-administration with most QTc-prolonging drugs or potent CYP3A4 inhibitors (e.g., certain antifungals or antibiotics) is strictly prohibited.

Patients with severe renal impairment can use the medicine, but require a significant dose reduction and reduced frequency. Pregnancy and lactation status requires careful clinical consideration, with guidance recommending to stop breastfeeding if the medicine is started, or to stop the treatment entirely.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Мотинорм (Domperidone) is structured by pharmacokinetic and pharmacodynamic constraints documented by regulatory authorities. Every restriction below reflects an officially verified risk of altered exposure or a combined adverse effect.

Interaction Structure

Classification Interacting Substance/Condition Restriction/Mechanism Statement (Regulatory)
Contraindicated (Metabolic) Potent CYP3A4 Inhibitors (e.g., Systemic Ketoconazole, Erythromycin) Formally prohibited; inhibition significantly increases Domperidone plasma concentrations and elevates risk of cardiac adverse effects.
Contraindicated (Pharmacodynamic) QTc-Prolonging Medicinal Products Formally prohibited due to the severe risk of additive pharmacodynamic effects on the cardiac QTc interval.
Timing Rule (Absorption) Antacids / Antisecretory Medicines Must not be co-administered; separation of administration time is required as these agents reduce oral bioavailability due to pH interference.
Exposure Alteration (PK Effect) Levodopa Co-administration leads to a documented increase in the plasma concentration of Levodopa.
Population Constraint (Clearance) Severe Renal Impairment The prolonged elimination half-life necessitates a reduction in dosing frequency to prevent accumulation.
Population Constraint (Condition) Moderate or Severe Hepatic Impairment Use of the medicine is formally prohibited due to the impact of impaired liver function on drug clearance.

The most stringent constraints are driven by the absolute necessity to prevent substantial increases in Domperidone exposure, primarily through prohibiting CYP3A4 inhibition, and by mitigating the risk of additive cardiac effects with other QTc-prolonging agents. These core regulatory restrictions define the mandatory contraindicated combinations and establish specific timing rules for co-administering agents that interfere with gastrointestinal absorption.

Advertisements

Mechanism of Action

How Мотинорм Works

Peripheral Dopamine mathbfD2 Receptor Antagonism

Мотинорм operates as a selective blocker, or antagonist, of mathbfD2 receptors. Its primary sites of action are located outside the central nervous system (CNS), specifically in the Chemoreceptor Trigger Zone (CTZ) and the enteric nervous system (ENS) of the gut wall. By engaging these target receptors, the drug counteracts the inhibitory signaling of dopamine. This antagonism of the mathbfD2 receptor initiates a signaling cascade that modulates the activity patterns responsible for nausea generation and digestive tract movement.


⬆️ Regulation of Upper Gastrointestinal Motility

The blockade of mathbfD2 receptors within the gastrointestinal tract removes a natural inhibitory restraint on the release of acetylcholine (ACh) from nerve endings in the myenteric plexus. This increase in the availability of the excitatory neurotransmitter, ACh, facilitates stronger and better-coordinated muscle contractions in the stomach and duodenum. This neurochemical adjustment directly influences the rate of postprandial gastric emptying and antroduodenal coordination.


Restricted Central Nervous System (CNS) Activity

The physicochemical properties of the drug confer limited penetration across the blood-brain barrier (BBB). Consequently, its pharmacological engagement is largely restricted to peripheral systems and circumventricular organs like the CTZ. This characteristic limits the interaction with mathbfD2 receptors situated within the brain parenchyma.

Advertisements

Dosage and Administration Information

How to Use Мотинорм

This section describes the administration and dosage protocols for Domperidone (Мотинорм), focusing on how the medicine is used in practice.


Official Routes and Forms

Мотинорм is approved for Oral and Rectal administration. Oral forms include 10 mg tablets and liquid suspensions or drops, while the rectal route is facilitated by 30 mg suppositories for adults.


Administration Protocol

Usage Entity Official Instruction
Standard Oral Dose 10 mg per dose (Adults/Adolescents 35 kg or more).
Maximum Daily Dose Strictly limited to 30 mg (oral) or 60 mg (rectal) per 24 hours.
Timing Relative to Food Oral forms must be taken before meals (e.g., 15 to 30 minutes prior), as food delays drug absorption.
Frequency Dosing is typically up to three times daily (oral), with doses separated by approximately eight hours.
Acute Duration Limit Treatment for acute symptoms should be for the shortest duration possible, generally not exceeding seven days.

Special Procedural Conditions

For accurate dosing, liquid oral forms must be measured using a calibrated measuring device. In cases of severe renal impairment, the dosing frequency must be reduced (e.g., to once or twice daily) due to prolonged clearance, which defines a mandatory usage pattern adjustment. If a dose is missed, it should be omitted, and the patient should resume the regular schedule; the dose must not be doubled.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Мотинорм

Evidence for Use in Nausea and Vomiting

Research has primarily focused on studies related to acute nausea and vomiting using short-term Randomized Controlled Trials (RCTs) and subsequent analyses. This work examines how patient-reported symptoms are measured over a brief time period. Findings from trials involving adults and adolescents often describe patterns in measured outcomes related to these acute symptoms. The evidence derived from these settings relates to temporary physiological imbalance and covers a typical observation interval of up to a week.

Studies report that the follow-up durations in the evidence base were limited. Data on sustained outcomes or effects beyond the initial acute phase are not extensive. Furthermore, studies examining certain groups, such as children with acute gastroenteritis, reported that observed measurements related to reducing vomiting episodes were not measurably different from those seen with placebo in that specific context.

Research Structure for Gastroparesis (Delayed Gastric Emptying)

Research related to gastroparesis, a condition involving chronic issues with stomach movement, was evaluated in specialized research contexts. This work includes randomized withdrawal studies and data from programs that investigated the medicine in patients with symptoms refractory to other treatments. The medicine was studied for its application in conditions characterized by functional limitations, often focusing on adults with diabetic gastroparesis.

Research evaluated patient-reported outcomes related to symptom intensity, such as overall discomfort scales (GCSI scores), and, in some cases, observed physiological strain by measuring actual stomach emptying time. The evidence is predominantly derived from smaller, specialized study designs rather than large-scale RCTs. Therefore, certainty about broad applicability remains low. The results apply only to the specific populations studied, and comparative evidence is lacking in some subgroups.

Key Uncertainties and Research Gaps

Research provides context but not individual predictions, and the overall evidence landscape highlights several key limitations. The most notable limitation is that follow-up durations were limited across the most robust trials, meaning data on long-term outcomes are not extensive. Research exploring use in certain groups, such as infants and young children, provides limited evidence. Research is ongoing to better understand the appropriate role of the medicine in specific conditions characterized by functional limitations.

Key Studies & References

  1. Domperidone in the treatment of gastroparesis and functional dyspepsia: a comprehensive review of the contemporary clinical landscape
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Мотинорм (FAQ)


Q: What is the difference between Мотинорм and other anti-nausea medications like metoclopramide?

Мотинорм (Domperidone) has limited ability to cross the blood-brain barrier (BBB), which typically results in minimal activity on the central nervous system. This peripheral focus contrasts with some other anti-nausea medications that have greater central nervous system engagement.


Q: What kind of mental or mood changes are sometimes associated with Мотинорм?

Regulatory information indicates that uncommon side effects can include feeling anxious or nervous. Less commonly, effects such as agitation, nervousness, or somnolence (drowsiness) have also been reported.


Q: Does Мотинорм interfere with the absorption of other oral medications?

Yes, co-administering Мотинорм with antacids or medicines that suppress stomach acid (antisecretory agents) reduces its absorption, which is why separation of administration time is officially advised. Official information also states that combining it with Levodopa can increase the plasma concentration of Levodopa.


Q: Is Мотинорм used for increasing breast milk supply, and what is the scientific evidence for this?

The drug is known to increase prolactin levels, which can lead to side effects like galactorrhea (unusual milk production). However, regulatory bodies note that use for this purpose is generally considered off-label, and evidence regarding its effectiveness and safety for this purpose remains limited.


Q: Can a patient with a history of breast cancer use Мотинорм?

Some tissue culture studies suggest that certain human breast cancers are dependent on the hormone prolactin. Because Мотинорм can increase prolactin levels, the situation requires careful clinical consideration. However, long-term use has not been definitively linked to mammary tumors in clinical studies.


Q: What is the connection between Мотинорм and Parkinson's disease treatment?

Мотинорм may be used to help treat nausea and vomiting caused by certain medications used for Parkinson's disease, such as levodopa. It is favored in this situation because its action is primarily peripheral, reducing potential interference with central nervous system treatments.


Q: What is the relationship between Мотинорм and changes in menstruation?

Official product information notes that changes in the menstrual period have been reported as uncommon side effects. These changes may include irregular periods or amenorrhea (the absence of periods).


Q: Is Мотинорм primarily a treatment for symptoms or does it address the underlying cause of stomach issues?

Мотинорм is officially approved for the relief of symptoms. It functions as both an antiemetic (relieving sickness) and a prokinetic agent (improving gut movement) to manage symptoms related to nausea, vomiting, and impaired gastrointestinal motility.


Q: Is it safe to use Мотинорм with common pain relievers or fever reducers?

Regulatory warnings focus on avoiding strong inhibitors of the CYP3A4 enzyme or other QTc-prolonging medicines. Common over-the-counter pain relievers or fever reducers are not typically listed as formal contraindications. Patients should consult their product information leaflet regarding combinations with other medicines.


Q: Should I avoid certain foods or drinks while taking Мотинорм?

Grapefruit and grapefruit juice may interact with the medicine, potentially increasing the risk of side effects, and are generally advised to be avoided. Additionally, oral forms must be taken before meals because food can significantly delay the drug’s absorption into your system.


Q: Do women experience different side effects from Мотинорм compared to men?

Yes, the official side effect profile includes adverse reactions that are specific to reproductive hormones. These include changes in menstruation and unusual milk production (galactorrhea) in women, and breast enlargement (gynaecomastia) and decreased libido in men.


Q: Is Мотинорм available over the counter or is it only by prescription?

Due to concerns over the potential for serious cardiac side effects, Domperidone (Мотинорм) has been restricted to a prescription-only medicine (POM) status in many regions, including the European Union and the United Kingdom.


Q: Can Мотинорм help with nausea caused by migraine headaches?

Some authoritative sources note that Domperidone may be used to address symptoms like nausea and vomiting that accompany migraine headaches. However, it is important to note that this specific use may be considered outside of the core licensed indication in certain regions.


Q: Is it normal for my stomach discomfort to resolve quickly (within a few days) on Мотинорм?

The medicine is intended for the treatment of acute symptoms and is typically prescribed for the shortest duration possible, generally not exceeding one week. This regulatory guidance suggests that relief is expected relatively quickly after beginning treatment.


Q: What is the function of the 'chemoreceptor trigger zone' (CTZ) that Мотинорм acts on?

The Chemoreceptor Trigger Zone (CTZ) is a specialized area in the brainstem that acts as a surveillance point, detecting toxins or disturbances in the blood. Мотинорм acts on this zone, blocking signals that trigger the sensation of nausea and the act of vomiting.


Q: Are there any known non-drug interactions with Мотинорм, like with herbal supplements?

Regulatory guidance advises caution regarding the use of herbal remedies and supplements. Patients are advised to use caution and consult their product information regarding herbal remedies and supplements, as they may not have been tested alongside this medicine.


Q: Does Мотинорм come in different strengths, and why is this important?

Мотинорм is available in different forms, such as oral tablets, oral drops, and suppositories, which have different active ingredient amounts. This is important because regulatory authorities have set a strict maximum daily dose limit to mitigate the risk of serious cardiac side effects.


Q: Is it normal to experience stomach cramps or diarrhea when first starting Мотинорм?

Official information lists both diarrhea and abdominal cramps as uncommon side effects that have been reported with the use of this medication.

Advertisements

How should Мотинорм be stored and disposed of?

Official Storage and Disposal Requirements

Motinorm (Domperidone) must be stored and handled according to regulatory standards to maintain its integrity and ensure public safety.

Requirement Type Official Labeled Condition
Temperature Store below 30 C (or 25 C, depending on formulation).
Environmental Protection Protect from light, moisture, and do not freeze.
Container Rule Keep in the original container and ensure it is tightly closed.
Safety Keep strictly out of the sight and reach of children.
Disposal Do not dispose of unused or expired medicine via household waste or wastewater; follow local regulatory requirements.

These conditions define the necessary physical environment for product stability and ensure mandated child-safety precautions are followed. Disposal must adhere to national guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Мотинорм found in:

A-Z Index: